Skip to main content
Home > BioCentury on BioBusiness > Finance/Investment

Chronological Index of : Finance

 Current Issue
  • Advancing apoptosis

    Ascentage to push forward with apoptosis candidates with $72M B round

    Ebb & Flow Advancing apoptosis A RMB500 million ($72 million) series B round will enable Ascentage Pharma Group Corp. Ltd. to generate clinical proof-of-concept data for two to three cancer candidates in three years.…

    Published on 1/16/2017
  • JPM jump

    Gainers, decliners in the wake of 2017 JPMorgan Healthcare Conference

    Ebb & Flow JPM jump Table: JPMorgan movers Nine of the 160 biotechs that presented at the 2017 JPMorgan Healthcare Conference not only skated through the volatile week unharmed, but managed to post gains of at …

    Published on 1/16/2017
  • Omega's trans-Atlantic bridge

    How Omega, NeoMed alliance aims to bridge U.S. and Europe venture investing

    Omega Funds' alliance with NeoMed Management. Plus: Ascentage's bountiful B round; and Ariad leads the pack at JPMorgan.

    Published on 1/16/2017
  • Table: JPMorgan movers

    JPM jump JPMorgan movers Biotechs presenting at the 2017 JPMorgan Healthcare Conference were down a median of 1% last week, in line with the NYSE Arca Biotechnology Index (BTK). At least 160 biotechs presented, …

    Published on 1/16/2017
  • Figure: Money Raised in 2017

    Omega's trans-Atlantic bridge Money Raised in 2017 Last week, the biotech industry raised $166 million, bringing to $1.4 billion the total raised year-to-date. In 2016, a total of $84.6 billion was raised, …

    Published on 1/16/2017
  • Tiers of disappointment

    Bad year for biotech ends on sour note in 4Q16 with all market cap tiers in red

    Biotech's bad year ended on an even more sour note with all market cap bands down significantly in 4Q16.

    Published on 1/9/2017
  • Figure: Money Raised in 2017

    Billion dollar baby Money Raised in 2017 Last week, the biotech industry raised $1.2 billion, bringing to $1.2 billion the total raised year-to-date. In 2016, a total of $84.6 billion was raised, including $49.4 …

    Published on 1/9/2017
  • Figure: Biotech fund flows

    Good riddance Biotech fund flows About $5 billion flowed out of biotech funds in 2016 vs. net inflows of $6 billion in 2015. November saw the largest inflows of the year — at $1.2 billion — as the BioCentury 100 …

    Published on 1/9/2017
  • Figure: M&A activity

    Good riddance M&A activity While the number of M&A deals in 2016 nearly kept pace with the prior year, aggregate value was down. Last year 84 deals were valued at $86 billion. In 2015, 85 deals were valued at a …

    Published on 1/9/2017
  • Figure: Raised by market cap

    Good riddance Raised by market cap Last year, 437 public companies raised $51.5 billion, representing 59% of the record-setting $86.7 billion raised by 501 companies in 2015. All market cap segments saw a decline …

    Published on 1/9/2017
  • Table: Follow-on performance

    Good riddance Follow-on performance Biotech companies raised $10.4 billion in 159 follow-ons in 2016, about one-third of the $29.6 billion raised in 224 offerings in 2015. Market caps for the 2016 class are down a…

    Published on 1/9/2017
  • Table: IPO performance

    Good riddance IPO performance Fifteen companies raised $4 billion in IPOs in 4Q16, bringing the total for the year to $7.2 billion. That's behind the $8.2 billion raised in 2015 but still the fourth-highest total …

    Published on 1/9/2017
  • Table: IPO queue

    Good riddance IPO queue At least nine companies have announced plans to go public since the start of 4Q16, bringing the IPO queue to at least 21. Unless noted, companies are seeking to list on NASDAQ. Filings are …

    Published on 1/9/2017
  • Billion dollar baby

    Grail dwarfs the private diagnostics space with a planned $1B series B round

    Ebb & Flow Ebb & Flow Billion dollar baby Figure: Money Raised in 2017 With what could be more than a $1 billion B round in the works, cancer screening company Grail Inc. is on track to set a new private …

    Published on 1/9/2017
  • Preparing to strike

    How Ascletis will use its $100M B round to expand beyond HCV

    Ebb & Flow Preparing to strike With $100 million in hand Ascletis BioScience Co. Ltd. is poised to repeat what it has done in HCV by hunting for new liver therapies for the China market. On Jan. 3, Ascletis closed …

    Published on 1/9/2017
  • Neon's next steps

    Neon plans to deploy its $70M B round across three neoantigen programs

    Ebb & Flow Neon's next steps Neon Therapeutics Inc.'s $70 million B round gives the company enough fuel to run three neoantigen programs in parallel. Partner Fund Management led the round, which closed on Jan. 5. …

    Published on 1/9/2017
  • Figure: London vs. Europe

    Tiers of disappointment London vs. Europe For 2016, the BioCentury Europe index gained 11%, while the BioCentury London fell 2%. Ten of 19 continental European companies in the market cap-weighted benchmark …

    Published on 1/9/2017
  • Figure: Price-to-earnings: BT vs. RX

    Tiers of disappointment Price-to-earnings: BT vs. RX Biotech's average P/E ended 4Q at 18.5, up 2% from 3Q16 but down 23% from a year ago. While six of 10 big biotechs saw their multiples decline from 3Q16 to 4Q16…

    Published on 1/9/2017
  • Figure: Results by market cap

    Tiers of disappointment Results by market cap All market cap segments declined in 4Q16 to finish 2016 in the red. The under $200 million group trailed all tiers in 4Q by posting double-digit losses. For the year, …

    Published on 1/9/2017
  • Table: 4Q approvals

    Tiers of disappointment 4Q approvals Selected 4Q approvals. Company Approval Bristol-Myers Squibb Co. (NYSE:BMY) / Merck & Co. Inc. (NYSE:MRK) FDA approves Zinplava bezlotoxumab to reduce the recurrence of …

    Published on 1/9/2017
  • Table: Index performance

    Tiers of disappointment Index performance Index 4Q16 2016 BioCentury Europe 11% 11% DJIA 8% 13% S&P 500 3% 10% NASDAQ Composite 1% 8% NYSE Arca Pharmaceutical -6% -11% BioCentury London -6% -2%…

    Published on 1/9/2017
  • Good riddance

    Why investors think 2017 will be an up year for biotech despite macro uncertainty

    Investors hope low valuations and impoverished pipelines could drive enough M&A to boost biotech performance in 2017.

    Published on 1/9/2017
  • Delivering takeouts

    25th annual Buyside View sees investors eyeing mid-cap M&A targets in 2017

    BioCentury's 25th annual Buyside View finds investors eyeing mid-caps with late-stage or marketed products that could become M&A targets.

    Published on 1/2/2017
  • Table: Approval watch

    Delivering takeouts Approval watch Selected products up for approval in 2017. (A) Uses Enhanze recombinant human hyaluronidase (rHuPH20) drug delivery technology from Halozyme Therapeutics Inc. (NASDAQ:HALO); …

    Published on 1/2/2017
  • Table: New products to watch

    Delivering takeouts 2017 milestones Selected products with clinical milestones or regulatory submissions expected in 2017. Source: BCIQ: BioCentury Online Intelligence Company Product Indication Event …

    Published on 1/2/2017

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993